Invasive Urothelial Carcinoma — Trials

Invasive Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

48 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 27
Recruiting: 15
Ph III recruiting: 2
Growth YoY: —
Industry share: 4%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02818725	I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations(GETUG-AFU19)	completed	Phase 3	133	UNICANCEROTHER	1	Mar 9, 2021	clinicaltrials

Data updated 23 days agoSource updated Mar 9, 2021source: clinicaltrials